|2.||Rosacea (Acne Rosacea)
|1.||Ferguson, J: 9 articles (04/2014 - 10/2000)|
|2.||Dawe, R S: 9 articles (04/2014 - 10/2000)|
|3.||Gold, Michael H: 8 articles (10/2014 - 07/2002)|
|4.||Halliday, Gary M: 8 articles (08/2010 - 07/2003)|
|5.||Rhodes, Lesley E: 7 articles (09/2015 - 11/2004)|
|6.||Katayama, Ichiro: 7 articles (08/2015 - 07/2004)|
|7.||Ferguson, James: 7 articles (06/2015 - 03/2003)|
|8.||Wulf, Hans Christian: 7 articles (05/2015 - 09/2003)|
|9.||Kim, Myeung Nam: 7 articles (01/2015 - 01/2008)|
|10.||Puglia, Carmelo: 7 articles (06/2014 - 02/2003)|
|1.||Sunscreening Agents (Sunscreens)IBA
08/01/2001 - "Sunscreens were found to confer significantly less protection against UV-induced immunosuppression than against UV-induced erythema."
01/01/2002 - "This means that sunscreens which mainly absorb UVB (protection against erythema) may be less effective in preventing UVR-induced immunosuppression than broad-spectrum products. "
11/01/2001 - "This means sunscreens that mainly absorb ultraviolet B (protection against erythema) may be less effective in preventing ultraviolet radiation-induced immunosuppression than broad-spectrum products. "
01/01/2001 - "Moreover, the protective effects of sunscreens against erythema and DNA damage also show wide interindividual variation. "
04/01/2000 - "Several studies have indicated that sunscreens that are designed to protect against erythema failed to give comparable protection against ultraviolet radiation-induced immunosuppression. "
|2.||brimonidine (Alphagan)FDA LinkGeneric
09/01/2015 - "Brimonidine gel is a highly selective α2-adrenergic receptor agonist with potent vasoconstrictive effects, which leads to significant reduction of persistent facial erythema in the majority of patients when applied once daily. "
08/01/2015 - "A detailed analysis of adverse events is needed to accurately define worsening erythema and the adverse-events profile associated with brimonidine gel treatment. "
01/01/2015 - "For example, real-world use has shown that a percentage of patients (in our experience, approximately 10 to 20%) treated with brimonidine experience a worsening of erythema that has been called "rebound." Our routine use of this agent for >1 year has yielded strategies to set patient expectations, optimize treatment initiation, and minimize potential problems; this article details those strategies. "
05/01/2014 - "Brimonidine, which was US FDA approved last year and recently sanctioned by Health Canada, has filled an essential therapeutic void in the targeted treatment of diffuse facial erythema. "
05/01/2014 - "Brimonidine effective but may lead to significant rebound erythema."
|3.||Tacrolimus (Prograf)FDA LinkGeneric
07/01/1999 - "Compared with the vehicle controls, sites treated with tacrolimus ointment (with or without penetration enhancer) showed a significant reduction in erythema and infiltration (P < 0. "
03/01/2003 - "Eyelid induration, erythema, and eczematous changes were substantially improved within 1 to 3 weeks after initiation of topical tacrolimus treatment in all patients. "
11/01/2006 - "A dose- and vehicle-controlled study on the pretreatment and posttreatment effect of 0.1% tacrolimus ointment on erythema induced by solar-simulated ultraviolet (UV) radiation was performed. "
08/01/2002 - "Investigator scores for erythema in the tacrolimus group were significantly lower than those in the placebo group at the end of the study (P = 0.005). "
09/01/2015 - "Erythema Dyschromicum Perstans: Response to Topical Tacrolimus."
06/01/2006 - "We conducted prospective randomized vehicle-controlled clinical trials to assess the anti-irritative efficacy of cosmetic formulations containing LicA in a post-shaving skin irritation model and on UV-induced erythema formation. "
09/01/2012 - "Clinical efficacy of a serum integrating multiple cosmetic ingredients in the management of erythema of the face in aging skin."
05/01/1975 - "The protection against erythema belongs to the cosmetic effects which lend themselves to mathematical treatment. "
01/01/2004 - "At concentrations higher than used in cosmetics, Glyceryl Laurate did cause moderate erythema in human repeat-insult patch test (RIPT) studies, but the other glyceryl monoesters tested failed to produce any significant positive reactions. "
06/01/2011 - "Cosmetic outcome was evaluated as fair because of residual erythema. "
|5.||Metronidazole (Metric)FDA LinkGeneric
03/01/2005 - "However, a significant reduction in erythema was seen in the metronidazole group. "
11/01/2002 - "Treatment with metronidazole 1% cream with sunscreen SPF 15 resulted in significant improvement (p <0.05) in inflammatory lesion count, erythema and telangiectasiae scores, and investigator and patient global assessment scores compared with baseline and placebo. "
07/01/2012 - "Erythema and oily face decreased by 85.7% and 87.1%, respectively, on the metronidazole-treated side. "
09/01/2005 - "Erythema annulare centrifugum successfully treated with metronidazole."
11/01/2001 - "The overall percentage change in erythema scores at endpoint for patients in the 0.75% metronidazole cream treatment group was -26% compared with -30% for patients in the 1.0% metronidazole cream treatment group. "
|6.||Adrenal Cortex Hormones (Corticosteroids)IBA
04/01/2015 - "These findings indicate that the use of a boswellia-based cream is effective in reducing the use of topical corticosteroids and is able to reduce the grade of erythema and the skin superficial symptoms, being well tolerated by the patients. "
08/01/1981 - "The effects of systemic corticosteroids on ultraviolet-induced delayed erythema were observed in a double-blind controlled study. "
12/01/1977 - "[The minimal erythema-swelling time as a parameter in studies on the effectiveness of external corticosteroids]."
01/01/2010 - "We report a case of GGA presenting as arcuate dermal erythema with excellent therapeutic response to corticosteroid therapy (a short course of intramuscular corticosteroids, a prolonged low oral dose, and topical corticosteroids)."
06/01/2009 - "To determine whether or not suppression of delayed UV erythema by a systemic corticosteroid could provide a useful model for assessing the anti-inflammatory potency of systemic corticosteroids. "
|7.||calcipotriene (calcipotriol)FDA LinkGeneric
03/01/2013 - "Incidence of adverse events in both treatment groups was low; calcipotriene foam, 0.005%, was associated with erythema. "
03/01/2013 - "Body involvement, target lesion score, and improvement for erythema, scaling, and plaque thickness were also assessed.<BR> At week 8, more subjects in the calcipotriene foam, 0.005% group (40.9%) met the primary end point vs the vehicle foam group (24.2%; intent-to-treat [ITT] population; P <.001); a significant difference between groups was also observed at weeks 2 (P = .041) and 4 (P <.001). "
02/01/2002 - "Calcipotriol for erythema annulare centrifugum."
06/01/2000 - "No difference in erythema was seen between calcipotriol medication and the vehicle controls. "
06/01/2000 - "Calcipotriol ointment and cream were applied in 19 and 18 subjects, respectively, and erythema was measured for each application time quantified. "
|8.||Indomethacin (Indometacin)FDA LinkGeneric
03/01/1992 - "Prostaglandin inhibition was demonstrated by a significant reduction of UVB erythema at the indomethacin-treated sites compared to the gel-base-treated sites. "
10/01/2001 - "Ultraviolet-B-induced erythema (one, two, or four times the minimal erythema dose) was reduced but not abolished by application of 1% indomethacin gel immediately after irradiation of human skin. "
08/01/2001 - "Test areas treated with indomethacin 60 min and 5 min before irradiation showed the significantly lowest visual erythema scores and no significant changes in skin mechanical parameters. "
08/01/2001 - "Topical indomethacin has been reported to inhibit ultraviolet light-induced erythema. "
10/01/1996 - "Indomethacin inhibited 300 and 320 nm (UVB) erythema, had no effect at 330 and 340 nm (UVA2), but augmented 350 and 370 nm (UVA1) erythema. "
|9.||Prednisolone (Predate)FDA LinkGeneric
06/01/2009 - "The threshold UV erythema suppression model assessed in this study could not distinguish between oral prednisolone and placebo. "
06/01/2009 - "Oral prednisolone did not significantly suppress the threshold UV erythema response (MED). "
06/01/2009 - "Delayed ultraviolet erythema not suppressed by oral prednisolone: a randomized crossover study."
01/01/1987 - "The density of these cells was significantly less in clinically negative reactions than in those with erythema or induration, but was unrelated to the presence or absence of a history of treatment with prednisolone. "
11/01/1963 - "[ON THE USE OF A NEW DERIVATIVE OF PREDNISOLONE, FOR TOPICAL APPLICATION, IN THE TREATMENT OF UNCOMPLICATED SOLAR ERYTHEMA]."
|10.||Cetirizine (Zyrtec)FDA LinkGeneric
08/01/1994 - "During the 8 weeks of the study, diary card scores showed a statistically significant decrease in erythema and other cutaneous symptoms, such as lichenification, in the cetirizine group. "
12/01/2014 - "At a later time, she took cetirizine for a cold, and developed palmar erythema and desquamation. "
10/01/2006 - "In contrast, cetirizine did not influence the 24 hour minimal phototoxic dose or erythema dose-response. "
11/01/2002 - "Erythema gyratum repens responding to cetirizine hydrochloride."
02/01/1999 - "In contrast, cetirizine did not influence the size of erythema and the magnitude of sensation in AE patients. "
08/01/2006 - "A significant reduction of the MN-induced erythema was observed with the Chromameter and Laser Doppler measurements for the following treatment modalities: (1) electrically assisted delivery: respectively, 65% and 100%, (2) application under a contact sponge: 66% and 97% and (3) passive diffusion without any covering: 32% and 65%. "
11/01/2000 - "The laser treatment had a significantly higher erythema score at 1 month and a small but significantly greater improvement in perioral wrinkles at 6 months. "
12/01/1998 - "Global assessment scores and erythema spectrometry measurements were significantly improved after laser treatment. "
09/01/2009 - "Day 7, post-laser treatment, resulted in a greater improvement in erythema, and re-epithelization of the peri-oral and peri-ocular regions in subjects using the active lotion vs. placebo control as determined by blinded, clinical evaluation of gross photographs and bioinstrumental mexameter measurements. "
02/01/2015 - "While traditional dosimetry for laser has been determined either through minimal erythema dose (MED) or a combination of the patient's Fitzpatrick skin type and the level of plaque induration, we have developed "Plaque-based Sub-blistering Dosimtery" based on observations that administering anywhere from 8 to 16 multiples of MED to psoriatic plaques has resulted in clearance after one treatment with longer remission rates than the traditional dosing protocol. "
01/01/2015 - "The treatment resulted in statistically significant improvement in erythema grade at 1, 2, and 3 months after treatment when compared with baseline (p < .05, p < .001, and p < .05, respectively). "
09/01/1990 - "Giant weals, weals, erythema and oedema were improved in both treatment groups after treatment for 1-4 weeks. "
01/01/2015 - "There was no rebound or worsening of erythema after treatment cessation.Topical"
01/01/2015 - "The mean baseline erythema grade was 1.80 (±0.56), and the mean erythema grade at 3 months after treatment was 1.00 (±0.38). "
12/01/2013 - "Post-treatment erythema was observed in most patients, and notable bruising after treatment observed in five patients resolved spontaneously within 7 days. "
|3.||Phototherapy (Light Therapy)
07/01/2004 - "Erythema (t=12.1, p<0.0001), excoriations (t=10.1, p<0.0001) and vesiculation improved most dramatically after UVA/UVB phototherapy. "
03/01/1998 - "UVB phototherapy in small doses was very effective for the persistent eruption, and no recurrence of the eruption was noted during or since the six-month maintenance therapy (once a week at a dose equivalent to 0.75 of the minimal erythema dose) (9 months total). "
01/01/2015 - "Efficacy of narrowband UVB phototherapy in erythema dyschromicum perstans treatment: case reports."
12/01/2014 - "A semiautomated hand-held device has been introduced in some phototherapy centres to establish the minimal erythema dose (MED) before treatment with narrowband ultraviolet (NBUV) B. "
12/01/2014 - "Comparison of a semiautomated hand-held device to test minimal erythema dose before narrowband ultraviolet B phototherapy with the conventional method using matched doses."
09/01/2013 - "Additionally, pulsed dye laser treatment improved postinflammatory erythema in the authors' patients. "
10/01/2004 - "We sought to assess improvement in erythema, symptoms, and quality of life after pulsed dye laser treatment. "
10/01/2005 - "After initial pulsed dye laser treatment, significant flattening and reduction of erythema were evident within the treated area. "
01/01/2003 - "We confirm that pulsed dye laser is a good alternative treatment for the erythema in active cutaneous lesions of lupus erythematosus (LE)."
09/01/2000 - "To evaluate the response of KPA to treatment with the pulsed dye laser (PDL) with regard to improvements in erythema and skin roughness, treatment tolerability, and side effects. "
|5.||Drug Therapy (Chemotherapy)
03/01/1993 - "In 4 patients chemotherapy caused a partially ulcerated skin erythema in the buttocks, which was completely cured in all cases."
03/01/2015 - "All three patients whose extravasation event was detected during chemotherapy administration benefited from SWOP with acceptable side effects (e.g., erythema). "
05/01/2008 - "Out of 2186 patients who underwent chemotherapy, 44 cases of acral erythema were identified, representing an incidence of 2.01 % during the study period and 16.75 % of all cutaneous lesions attributed to chemotherapy. "
05/01/2008 - "The study included all patients who developed acral erythema lesions following chemotherapy between January 2000 and December 2003. "
05/01/2008 - "[Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases]."